Press Release / NEWS / IASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-T

NEWS

11/112026
IASO Bio Announces NMPA IND Approval for IASO208, Advancing Its In Vivo CAR-T Platform into Synchronized U.S.–China Clinical Development
10/112026
IASO Bio Announces Early Clinical Data from Investigator-Initiated Trial of Equecabtagene Autoleucel Injection in Patients with Refractory Lupus Nephritis at ACR Convergence 2026
05/112026
Expanding into Non-Oncology: IASO Biotechnology and Longuide Biopharma Announce LNP Collaboration

042026-11

IASO Bio Hosts FUCASO Singapore Launch Event, Marking the Official Commercial Landing of China's Original Fully Human BCMA CAR-T Cell Therapy in Southeast Asia's Healthcare Hub
262026-09

2026 IMS | IASO Bio Presented FUCASO China Real-World Data
262026-09

2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy Product IASO206
252026-09

2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T
252026-09

2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio’s FUCASO Reveals That In Vivo Durable Persistence of CAR-T cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression
162026-09

IASO Bio’s CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance
142026-09

IASO Bio Announces Completion of Enrollment in FUMANBA-3 Phase III Registrational Study of Equecabtagene Autoleucel for Second- and Third-Line Multiple Myeloma

Copyright © 2023 南京驯鹿生物技术股份有限公司　　　　苏ICP备2021047135号　　　　 Privacy Policy　|　Terms of Use